TY - JOUR
T1 - Comparison of midterm outcomes of transcatheter aortic valve implantation in patients with and without previous coronary artery bypass grafting
AU - On behalf of the OCEAN-TAVI Investigators
AU - Kawashima, Hideyuki
AU - Watanabe, Yusuke
AU - Kozuma, Ken
AU - Kataoka, Akihisa
AU - Nakashima, Makoto
AU - Hioki, Hirofumi
AU - Nagura, Fukuko
AU - Nara, Yugo
AU - Shirai, Shinichi
AU - Tada, Norio
AU - Araki, Motoharu
AU - Naganuma, Toru
AU - Yamanaka, Futoshi
AU - Ueno, Hiroshi
AU - Tabata, Minoru
AU - Mizutani, Kazuki
AU - Higashimori, Akihiro
AU - Takagi, Kensuke
AU - Yamamoto, Masanori
AU - Hayashida, Kentaro
N1 - Funding Information:
The authors thank the investigators and institutions participating in the OCEAN-TAVI registry. Drs. Watanabe, Shirai, Tada, Araki, Naganuma, Yamamoto, and Hayashida are proctors of transfemoral TAVI and Dr. Tabata is a proctor of transapical TAVI for Edwards Lifesciences. Drs. Watanabe, Shirai, Naganuma, and Yamamoto are proctors of transfemoral TAVI for Medtronic.
Publisher Copyright:
© 2018, Springer Japan KK, part of Springer Nature.
PY - 2018/10/1
Y1 - 2018/10/1
N2 - The midterm safety and feasibility of transcatheter aortic valve implantation (TAVI) for patients with a history of coronary artery bypass graft (CABG) and high operative risk are unclear. This study compared the midterm outcomes of patients undergoing TAVI with or without previous CABG surgery. Between October 2013 and July 2016, 1,613 patients underwent TAVI according to the Optimized CathEter vAlvular iNtervention (OCEAN)-TAVI registry (previous CABG: n = 120; no previous CABG: n = 1493). The propensity score comprised the variables of the Society of Thoracic Surgeons Score, previous myocardial infarction, peripheral artery disease, chronic kidney disease > stage 2 (estimated glomerular filtration rate < 60 mL/min/1.73 m2), and the TAVI approach method. After propensity matching, 118 patients were classified into the CABG and non-CABG groups. Kaplan–Meier analysis revealed that the incidence of overall cardiovascular death in the CABG group was significantly higher than in the non-CABG group (log-rank; p = 0.004). Overall mortality due to heart failure was higher in the CABG than in the non-CABG group (8.5 vs. 1.7%, p = 0.038). The present study demonstrated that patients with a history of CABG who underwent TAVI had a higher frequency of cardiovascular death, mainly due to heart failure. Heart failure detection and rigorous heart failure management are required after TAVI.
AB - The midterm safety and feasibility of transcatheter aortic valve implantation (TAVI) for patients with a history of coronary artery bypass graft (CABG) and high operative risk are unclear. This study compared the midterm outcomes of patients undergoing TAVI with or without previous CABG surgery. Between October 2013 and July 2016, 1,613 patients underwent TAVI according to the Optimized CathEter vAlvular iNtervention (OCEAN)-TAVI registry (previous CABG: n = 120; no previous CABG: n = 1493). The propensity score comprised the variables of the Society of Thoracic Surgeons Score, previous myocardial infarction, peripheral artery disease, chronic kidney disease > stage 2 (estimated glomerular filtration rate < 60 mL/min/1.73 m2), and the TAVI approach method. After propensity matching, 118 patients were classified into the CABG and non-CABG groups. Kaplan–Meier analysis revealed that the incidence of overall cardiovascular death in the CABG group was significantly higher than in the non-CABG group (log-rank; p = 0.004). Overall mortality due to heart failure was higher in the CABG than in the non-CABG group (8.5 vs. 1.7%, p = 0.038). The present study demonstrated that patients with a history of CABG who underwent TAVI had a higher frequency of cardiovascular death, mainly due to heart failure. Heart failure detection and rigorous heart failure management are required after TAVI.
KW - CABG
KW - Congestive heart failure
KW - Survival
KW - TAVI
UR - http://www.scopus.com/inward/record.url?scp=85045738642&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045738642&partnerID=8YFLogxK
U2 - 10.1007/s00380-018-1166-9
DO - 10.1007/s00380-018-1166-9
M3 - Article
C2 - 29680865
AN - SCOPUS:85045738642
SN - 0910-8327
VL - 33
SP - 1229
EP - 1237
JO - Heart and Vessels
JF - Heart and Vessels
IS - 10
ER -